相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia
Kechen Ban et al.
BLOOD (2008)
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib
Navratna Vajpai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase
Ji Wu et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors
H. Konig et al.
LEUKEMIA (2008)
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Charles G. Mullighan et al.
NATURE (2008)
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
Jorge Cortes et al.
BLOOD (2007)
Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression
D. Brazma et al.
GENES CHROMOSOMES & CANCER (2007)
Imaging hematopoietic precursor division in real time
Mingfu Wu et al.
CELL STEM CELL (2007)
Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease
Emily K. Thomas et al.
CANCER CELL (2007)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Leukemia stem cells in a genetically defined murine model of blast-crisis CML
Sarah J. Neering et al.
BLOOD (2007)
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia
Richard T. Williams et al.
GENES & DEVELOPMENT (2007)
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
Paolo Neviani et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P. Shah et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Junia V. Melo et al.
NATURE REVIEWS CANCER (2007)
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells
Xiaoyan Jiang et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia
Ellen Weisberg et al.
NATURE REVIEWS CANCER (2007)
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells
Heather G. Jorgensen et al.
BLOOD (2007)
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment
Cornelius Miething et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Brian J. Skaggs et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
Yiguo Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease
Melissa Kristine Middleton et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
Craig Kovitz et al.
BLOOD (2006)
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications
Ingo Roeder et al.
NATURE MEDICINE (2006)
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E. Jabbour et al.
LEUKEMIA (2006)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib
Ian J. Griswold et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Chronic myeloid leukemia:: Diagnosis and treatment
Alfonso Quintas-Cardama et al.
MAYO CLINIC PROCEEDINGS (2006)
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
Mateusz Koptyra et al.
BLOOD (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation
Andrea Hoelbl et al.
BLOOD (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
John S. Tokarski et al.
CANCER RESEARCH (2006)
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
Mhairi Copland et al.
BLOOD (2006)
Gene expression profiling of CD34+cells identifies a molecular signature of chronic myeloid leukemia blast crisis
C. Zheng et al.
LEUKEMIA (2006)
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition
Hans-Guido Wendel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A Src-like inactive conformation in the Abl tyrosine kinase domain
Nicholas M. Levinson et al.
PLOS BIOLOGY (2006)
Absence of the transcription factor CCAAT enhancer binding protein α results in loss of myeloid identity in bcr/abl-induced malignancy
K Wagner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation
M Notari et al.
BLOOD (2006)
Gene expression changes associated with progression and response in chronic myeloid leukemia
JP Radich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Molecular profiling of CD34(+) cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML
ASM Yong et al.
BLOOD (2006)
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
P Neviani et al.
CANCER CELL (2005)
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia
DJ Barnes et al.
CANCER RESEARCH (2005)
Stem cell research - Paths to cancer therapies and regenerative medicine
I Weissman
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Distinct molecular phenotype of malignant CD34+hematopoietic stem and progenitor cells in chronic myelogenous leukemia
R Kronenwett et al.
ONCOGENE (2005)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
TA Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization
JA Cancelas et al.
NATURE MEDICINE (2005)
Dynamics of chronic myeloid leukaemia
F Michor et al.
NATURE (2005)
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia
S Soverini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli
MS Holtz et al.
LEUKEMIA (2005)
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger et al.
BLOOD (2005)
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
A Quintas-Cardama et al.
BLOOD (2005)
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
R Ren
NATURE REVIEWS CANCER (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis
S Koschmieder et al.
BLOOD (2005)
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia
YG Hu et al.
NATURE GENETICS (2004)
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
NJ Donato et al.
CANCER RESEARCH (2004)
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2
Y Dai et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
CHM Jamieson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors
P Ramaraj et al.
CANCER RESEARCH (2004)
Imatinib therapy in chronic myelogenous leukemia:: strategies to avoid and overcome resistance
A Hochhaus et al.
LEUKEMIA (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks
MO Nowicki et al.
BLOOD (2004)
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors
BJP Huntly et al.
CANCER CELL (2004)
Regulation of the C-Abl and Bcr-Abl tyrosine kinases
O Hantschel et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells
E Passegué et al.
CELL (2004)
Clonal evolution in chronic myelogenous leukemia
J Cortes et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma
E Tian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias
S Jaiswal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia
BJP Huntly et al.
BLOOD (2003)
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
S Branford et al.
BLOOD (2003)
Autoinhibition of Bcr-Abl through its SH3 domain
KM Smith et al.
MOLECULAR CELL (2003)
Chronic myelogenous leukemia molecular signature
MO Nowicki et al.
ONCOGENE (2003)
Several Bcr-Ab1 kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib
AS Corbin et al.
BLOOD (2003)
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL
M Azam et al.
CELL (2003)
A myristoyl/phosphotyrosine switch regulates c-Abl
O Hantschel et al.
CELL (2003)
Structural basis for the autoinhibition of c-Abl tyrosine kinase
B Nagar et al.
CELL (2003)
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
CB Gambacorti-Passerini et al.
LANCET ONCOLOGY (2003)
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
NJ Donato et al.
BLOOD (2003)
Molecular and chromosomal mechanisms of resistance to imatinib (ST1571) therapy
A Hochhaus et al.
LEUKEMIA (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Critical role for Gab2 in transformation by BCR/ABL
M Sattler et al.
CANCER CELL (2002)
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9
AB Dash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
CL Sawyers et al.
BLOOD (2002)
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation
MS Holtz et al.
BLOOD (2002)
Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells
J Sonoyama et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
BCR-ABL suppresses C/EBP alpha expression through inhibitory action of hnRNP E2
D Perrotti et al.
NATURE GENETICS (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro
SM Graham et al.
BLOOD (2002)
Cytogenetic and molecular genetic evolution of chronic myeloid leukemia
B Johansson et al.
ACTA HAEMATOLOGICA (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
A model of human p210bcr/ABL-mediated chronic myelogenous leukemia by transduction of primary normal human CD34+ cells with a BCR/ABL-containing retroviral vector
RC Zhao et al.
BLOOD (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl
XW Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking JunB expression in the myeloid lineage
E Passegué et al.
CELL (2001)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder
SX Hao et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
分享论文
